News | Magnetic Resonance Imaging (MRI) | February 11, 2020
FMI finds increasing demand for image-guided surgical procedures to propel MRI contrast agents market growth
The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly

Image courtesy of GE Healthcare


February 11, 2020 — The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly in the foreseeable future, due to surging demand for image-guided surgical procedures, according to a new report from Future Market Insights (FMI). Advancements in diagnostic imaging and growing number of diagnostic centers offering magnetic resonance imaging (MRI) services create a significant opportunity for players operating in the MRI contrast agents market.

Increasing investments in the magnetic resonance imaging contrast agents market by key market players and new product launches are major factors expected to boost growth further. The global magnetic resonance imaging contrast agents market was valued at $765M in 2018, and is expected to exhibit a CAGR of 4 percent during the forecast period (2019–2029).
 

Key Takeaways of MRI Contrast Agents Market Study

  • Extracellular fluid (ECF) agents contributed more than three-fourth value share of the magnetic resonance imaging contrast agents market in 2018. This can be attributed to the availability of more patient-compliant products, and better clinical outcomes due to their brief vascular phase, rapid distribution in the extracellular space, and faster elimination through renal systems than other contrast agents.
  • Hospitals represented the highest market value share, followed by diagnostic centers, due to higher installed base of MRI units in hospitals and substantial visit to outpatient departments for the treatment and diagnosis of several disorders.
  • North America holds the highest revenue share in the global magnetic resonance imaging contrast agents market, owing to significant number of MRI scans performed with contrast agents.
  • Government initiatives toward the development of modern healthcare centers and financial support towards the growth of medical imaging technologies in Asian countries are expected to drive the growth of the magnetic resonance imaging contrast agents market in the region.

New Product Launches — Imperative Strategy for Market Players

Increasing introduction of new MRI contrast agents is the major factor responsible for intense competition among market players. Several companies are focusing on launching new magnetic resonance imaging contrast agents to increase their product sales and expand market share. For example, in March 2017, GE Healthcare launched Clariscan (gadoteric acid), a new macrocyclic MRI contrast agent, in Europe, and in July 2018 in South Korea.
 

Related content:


Related Content

Feature | Radiology Imaging

View the September/October digital edition of Imaging Technology News (ITN), including links to videos, comparison ...

Time September 29, 2022
arrow
News | Pediatric Imaging

September 29, 2022 — According to an open-access Editor’s Choice article in ARRS’ American Journal of Roentgenology (AJR ...

Time September 29, 2022
arrow
News | Radiology Imaging

September 27, 2022 — UK Biobank, the large-scale biomedical database and research resource, together with the Medical ...

Time September 27, 2022
arrow
News | Point-of-Care Ultrasound (POCUS)

September 27, 2022 — Fujifilm Sonosite, Inc. – the world leader in point-of-care ultrasound (POCUS) solutions – has ...

Time September 27, 2022
arrow
News | Prostate Cancer

September 26, 2022 — Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game ...

Time September 26, 2022
arrow
News | Artificial Intelligence

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Time September 22, 2022
arrow
News | Contrast Media

Editor’s note: On September 21, 2022, both Guerbet and Bracco Diagnostics released news detailing the FDA approval of a ...

Time September 22, 2022
arrow
News | Contrast Media

September 21, 2022 – Guerbet, a global medical imaging company, has announced that the U.S. Food and Drug Administration ...

Time September 21, 2022
arrow
News | Digital Radiography (DR)

September 16, 2022 — 20/20 Imaging, a division of Konica Minolta Healthcare Americas, Inc., announces the FDA clearance ...

Time September 16, 2022
arrow
Feature | Lung Imaging | By Christine Book

“Lung cancer is the deadliest cancer in men and in women, and it all boils down to how it is detected and when it is ...

Time September 16, 2022
arrow
Subscribe Now